Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Feb 22, 2021 7:10am EST

New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson

Feb 01, 2021 7:00am EST

Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

Jan 28, 2021 7:00am EST

Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”

Jan 08, 2021 7:00am EST

Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Dec 15, 2020 7:00am EST

Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs

Dec 14, 2020 7:00am EST

Can-Fite Reports on Progress With Its Namodenoson NASH Program

Dec 03, 2020 7:00am EST

Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020

Nov 30, 2020 7:00am EST

Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update

Nov 24, 2020 7:00am EST

Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD)

Nov 23, 2020 7:00am EST

Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET

  • arrow_back
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 37
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2023 Can-Fite All Rights Reserved

BrandWiz - Branding